INSULET $PODD Q3’26 EARNINGS HIGHLIGHTS
🔹 Revenue: $842M (Est. $833M) 🟢; +19.2% YoY
🔹 Adj. EPS: $1.99 (Est. $1.59) 🟢; +59.9% YoY
🔹 Adjusted EBITDA: $233.7M (Est. $196M) 🟢
🔹 Adjusted Oper Income: $185.2M (Est. $151M) 🟢
FY26 Guide:
🔹 U.S. Omnipod: +17.5%-+18.5%
🔹 International Omnipod: +32%-+33%
🔹 Total Omnipod: +21.5%-+22.5%
🔹 Drug Delivery: ~(40)%
🔹 Total Revenue: +21%-+22%
🔹 Adjusted Operating Margin: ~+150 bps YoY
🔹 Adjusted EPS Growth: >30%
Segment Net Revenue:
🔹 U.S. Omnipod: $570.4M; +14.7% YoY
🔹 International Omnipod: $266.2M; +31.7% YoY
🔹 Drug Delivery: $5.5M; -22.7% YoY
Announcements:
🔹 Omnipod Discover: >35,000 users; 5,000 healthcare professionals
🔹 Omnipod 5 Data: >384,000 people across 17 countries
Other Q3 Metrics:
🔹 Gross Margin: 75.1% GAAP; 74.2% adjusted
🔹 Total Omnipod Revenue: $836.6M; +19.7% YoY
Capital Return:
🔹 Share Repurchase Authorization: $1B
🔹 Q4 Repurchases: ~$400M
Comments:
🔸 “Our team delivered a strong quarter, with revenue growth of nearly 20% and significant margin expansion”
显示更多